Bringing the fundamentals into focus…
Back to Immunome, Inc.
How Immunome, Inc. stacks up
IMNM · against 454 other Healthcare companies listed in US-listed
Growth
8/ 100
Near the bottom of its peers.
Ranked #415 of 455 · scores higher than 7% of peers
Bars: peers in each 10-point band of the growth score44 peers with a growth score of 0–9, including IMNM · Click a bar to see the companies
Why growth scores 8?
Weighted metrics compared with all Healthcare companies.Mainly because of its revenue growth, which is weaker than most Healthcare peers.
- slower revenue growth over the last year: weaker than 100% of peers. Revenue growth: -100.0% vs peer median 6.1%
- 3-year revenue growth is not reported, so it is left out of the score.
- Still loss-making, but the loss per share narrowed. Earnings per share growth: — vs peer median 9.8%
Metric by metric
Position: dot = IMNM, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | IMNM | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Revenue growthHigher is better · 475 reported | -100.0% | 11.0% | 0% | 33% | |
| Earnings per share growthHigher is better · 171 reported | Not reported | 21.2% | — | — | 33% |
| 3-year revenue growthHigher is better · 433 reported | Not reported | 11.0% | — | — | 33% |
A metric that is not reported is left out of the score; the other weights are rescaled.
Ranking by growth score
Top 5 and the companies ranked around IMNM| Rank | Company | Market cap | Growth | Overall |
|---|---|---|---|---|
| 1 | 411M USD | 100 | 53 | |
| 2 | 1.4B USD | 99 | 73 | |
| 2 | 408M USD | 99 | 81 | |
| 2 | 8.5B USD | 99 | 31 | |
| 2 | 81M USD | 99 | 27 | |
| 412 | 341M USD | 9 | 14 | |
| 415 | 3.5B USD | 8 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score